Henry Tseng, DPM
Podiatrist · West Covina, CANPI 1295733855
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 66.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $6,667 and has fallen 86.0% since, to $936 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $63.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Paratek Pharmaceuticals, Inc.$793
- Smith+Nephew$649
- Cardiovascular Systems Inc.$369
- Stryker$342
- Inari Medical, Inc.$235
- plus $1K from 15 others
What the payments were for
- Consulting fees$4,05040%
- Travel & lodging$1,00810%
- Food & beverage$5,01150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 60 | $6,663 |
| Paratek Pharmaceuticals, Inc. | 41 | $793 |
| Smith+Nephew | 22 | $649 |
| Cardiovascular Systems Inc. | 3 | $369 |
| Stryker | 2 | $342 |
| Inari Medical, Inc. | 2 | $235 |
| Bioventus LLC | 2 | $178 |
| Abbott | 2 | $150 |
| AbbVie | 4 | $149 |
| Johnson & Johnson | 1 | $110 |
| Melinta Therapeutics, LLC | 5 | $96 |
| ANI Pharmaceuticals, Inc. | 3 | $90 |
| Angiodynamics, Inc. | 1 | $63 |
| Kowa Pharmaceuticals America, Inc. | 2 | $51 |
| Sebela Pharmaceuticals Inc. | 2 | $33 |
| Venclose Inc. | 1 | $27 |
| Boston Scientific | 1 | $17 |
| Hartmann USA, Inc. | 1 | $17 |
| Solventum Corporation | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$5,690
- Stravix$382
- Oasis$257
- Grafix$247
- PROPHECY$174
- AUGMENT INJECTABLE$168
- Diamondback Peripheral$147
- Peripheral Orbital Atherectomy System$146
- FLOWTRIEVER CATHETER, S$142
- CT THROMBECTOMY SYSTEM KIT$142
- Exogen$141
- GRAFIX PL$135
- GrafixPL$125
- ETERNA$120
- DALVANCE$106
How this compares
$10,069 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole | 964 | $27,656 |
| Oxiconazole Nitrate | 30 | $17,599 |
| Ciclopirox | 348 | $15,081 |
| CiclopiroxCiclopirox Olamine | 462 | $12,210 |
| Diclofenac Sodium | 130 | $11,852 |
| Naftifine Hcl | 44 | $11,810 |
| SantylCollagenase Clostridium Hist. | 17 | $11,368 |
| Econazole Nitrate | 108 | $8,267 |
| Ketoconazole | 85 | $7,412 |
| Hydrocortisone Butyrate | 15 | $6,993 |
| Ammonium Lactate | 216 | $4,609 |
| Lidocaine | 36 | $4,545 |
| Desoximetasone | 19 | $4,345 |
| CeftriaxoneCeftriaxone Sodium | 48 | $2,596 |
| Fluocinonide | 32 | $2,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $649 | $11,36817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 721 podiatrist providers in California.
Other podiatrist in West Covina
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.